Latest:
The Rationale for Investigating DNA-PK as a Target in Prostate Cancer
Karen E. Knudsen, PhD, discusses the rationale for investigating DNA-dependent protein kinase as a target in prostate cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Karen H. Lu, MD
Latest:
Dr. Lu on the Challenges of Risk-Reducing Salpingo-Oophorectomy in Ovarian Cancer
Karen H. Lu, MD, professor and chair in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center discusses the challenges of risk-reducing salpingo-oophorectomy in women with an increased risk for hereditary ovarian cancer.
Karen H. Ventii, PhD
Latest:
Beyond PSA: A Summary Review of Predictive/Prognostic Biomarkers in Prostate Cancer
Although prostate cancer (PC) is the most common solid tumor malignancy among men in the Western Hemisphere, disease-specific mortality remains low, primarily due to optimized screening, diagnosis, and treatment.
Karen Hande, DNP, ANP-BC, CNE
Latest:
Developing Best Practices to Mitigate Opioid Abuse Is a Priority in Cancer Care
Opioids are prescribed to manage cancer pain because the benefits generally outweigh the risks and because of the ethical imperative for quick relief. However, patients are exposed to a degree of risk for misuse and abuse.
Karen K. Ballen, MD
Latest:
Most Patients in Need of HCT Can Now Get Transplants
Due to great progress in alternative donor transplants, almost all transplant-eligible patients, up to age 75 years, in 2017 will be able to find a suitable donor and proceed to transplant, a major advance over the past 10 years.
Karen Masino, MS, CNP, ACNP-BC, AOCNP, RN, RD, LDN
Latest:
Screening and Management: Distress and the Nurse Navigator, Part II
Cancer and its treatment creates or aggravates psychosocial distress, while unresolved physical and practical problems can also add to the distress of patients attempting to complete their treatment and recovery.
Karen Reckamp, MD
Karen L. Reckamp, MD, is director of Medical Oncology, associate director of Clinical Research, and the medical oncology director of the Lung Institute at the Samuel Oschin Cancer Center at Cedars Sinai
Latest:
Dr Reckamp on the Future Implications of the PRAGMATICA-LUNG Trial in Lung Cancer
Karen L. Reckamp, MD, discusses the feasibility of future pragmatic clinical trials for patients with lung cancer.